# OnCo record paper-ruby-nejm-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-ruby-nejm-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-ruby-nejm-2023" ;
  schema:name "RUBY: dostarlimab with chemotherapy for advanced or recurrent endometrial cancer"@en ;
  schema:description "Adding the PD-1 antibody dostarlimab to first-line chemotherapy for advanced endometrial cancer cut progression by 72% in tumours with defective mismatch repair and by about a third overall, and later improved survival."@en ;
  schema:url <https://onco.cc/key-papers/paper-ruby-nejm-2023/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2216334>, <https://clinicaltrials.gov/study/NCT03981796> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2216334> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Mirza MR, Chase DM, Slomovitz BM, et al." ;
  onco:cancers <https://onco.cc/cancers/endometrial/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/histopathology-ihc/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/> ;
  onco:companies <https://onco.cc/companies/gsk/> ;
  onco:terms <https://onco.cc/terms/msi/>, <https://onco.cc/terms/pfs/>, <https://onco.cc/terms/os/>, <https://onco.cc/terms/first-line/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-immunotherapy-response/>, <https://onco.cc/bottlenecks/b-biomarker-validation/> ;
  onco:journals <https://onco.cc/journals/nejm/> .